The pharmaceutical landscape in 2026 continues to recognize methotrexate as a cornerstone of cost-effective therapy for chronic autoimmune and oncological conditions. According to the latest Methotrexate Market analysis, the global industry is valued at approximately USD 680.1 million this year. This valuation is underpinned by the drug's role as a primary "anchor drug" in combination therapies...